Nasdaq: $29.20 (-0.04) | AIM: £4.18 (-0.01)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China,  strive to create differentiated novel oncology and immunology treatments with global potential.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.